...
首页> 外文期刊>International Journal of Pharmaceutical Investigation >Formulation and optimization of mucoadhesive bilayer buccal tablets of atenolol using simplex design method
【24h】

Formulation and optimization of mucoadhesive bilayer buccal tablets of atenolol using simplex design method

机译:使用单纯形设计方法制备和优化黏膜粘连双层阿替洛尔口腔片剂

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction:In the present study, mucoadhesive buccal bilayer tablets of atenolol were fabricated with the objective of avoiding first pass metabolism and to improve its bioavailability with reduction in dosing frequency. Hence, the aim of this work was to design oral controlled release mucoadhesive tablets of atenolol and to optimize the drug release profile and bioadhesion.Materials and Methods:Bilayer buccal tablets of atenolol were prepared by direct compression method using simplex method of optimization to investigate the combined effect of hydroxypropyl methylcellulose 15 cps (X1), Carbopol (X2) and mannitol (X3); the in vitro drug release (Y1) and mucoadhesive strength (Y2) were taken as responses. The designed tablets were evaluated for various physical and biological parameters like drug content uniformity, in vitro drug release, short-term stability, and drug- excipient interactions (FTIR).Results:The formulation C containing hydroxypropyl methylcellulose 15 cps (10% w/w of matrix layer), Carbopol 934p (10% w/w of matrix layer) and mannitol (channeling agent, 40% w/w of matrix layer) was found to be promising. This formulation exhibited an in vitro drug release of 89.43% in 9 h along with satisfactory bioadhesion strength (7.20 g). Short-term stability studies on the promising formulation indicated that there are no significant changes in drug content and in vitro dissolution characteristics (P<0.05). IR spectroscopic studies indicated that there are no drug-excipient interactions.
机译:简介:在本研究中,阿替洛尔的粘膜黏膜颊黏膜双层片剂的制备旨在避免首过代谢,并通过降低给药频率来提高其生物利用度。因此,本研究的目的是设计口服阿替洛尔粘膜控释粘膜片,以优化药物的释放特性和生物粘附性。羟丙基甲基纤维素15 cps(X1),Carbopol(X2)和甘露醇(X3)的联合作用;以体外药物释放(Y1)和粘膜粘附强度(Y2)为响应。对所设计的片剂进行了各种物理和生物学参数评估,例如药物含量均匀性,体外药物释放,短期稳定性和药物-赋形剂相互作用(FTIR)。结果:含有羟丙基甲基纤维素15 cps(10%w /发现基质层的w),Carbopol 934p(基质层的10%w / w)和甘露醇(通道剂,基质层的40%w / w)是有希望的。该制剂在9小时内显示89.43%的体外药物释放以及令人满意的生物粘附强度(7.20 g)。对有前途的制剂进行的短期稳定性研究表明,药物含量和体外溶出特性没有明显变化(P <0.05)。红外光谱研究表明没有药物-赋形剂相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号